Effects of Autogenic Drainage and Flutter Device in COPD

Starting soon · Not applicable

Conditions studied: COPD (Chronic Obstructive Pulmonary Disease)

In brief

COPD is a progressive lung disease that includes emphysema and chronic bronchitis and is a major cause of morbidity and mortality worldwide. Airway clearance techniques help improve mucus removal, reduce dyspnea, and enhance quality of life in COPD patients. This study aims to compare the effects of autogenic drainage and flutter device on dyspnea, pulmonary function, and functional capacity in patients with COPD. A randomized clinical trial will be conducted at Gulab Devi Teaching Hospital using convenient sampling. Participants will be divided into two groups: Group A will receive autogenic drainage, while Group B will use the flutter device. Interventions will be performed daily for 20-30 minutes over 6 weeks. Outcome measures will include dyspnea severity scale, spirometry, and 6-minute walk test. Data will be analyzed using SPSS with significance set at p \< 0.05. The study may provide evidence for effective, non-invasive, and cost-effective management strategies for COPD patients.

Key facts

Study ID

NCT07713043

Run by

Riphah International University

People needed

42

Starts

2026-06-01

Expected to finish

2026-08-01

Last updated by the study team

2026-07-20

Who can join

Age: 40 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age group: Middle age adults (40-60 years), medically stable
• Both gender
• Diagnosis based on GOLD criteria ((FEV₁/FVC ratio < 0.70).
• Moderate COPD with no acute exacerbations in the past 4-6 weeks.
• Participants must be able to perform Autogenic drainage and Flutter device physically and mentally.
• Voluntary participation with consent.

You may not qualify if…

• Cardic Diseases (Acute MI, Congestive Heart Failure)
• Musculoskeletal Impairements
• Using Non-invasive Ventilation
• Recent lung diseases (Respiratory failure, pneumothorax)
• Hemodynamic instability
• Uncoorperative patients
• Cognitive Impairement scale
• Participants excluded if they did not consent
• Comorbidities affecting exercise tolerance

Where it is running

• Nimra Noor — Lahore, Punjab Province, Pakistan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.